KR20230024331A - 눈 장애의 치료를 위한 화합물 및 방법 - Google Patents

눈 장애의 치료를 위한 화합물 및 방법 Download PDF

Info

Publication number
KR20230024331A
KR20230024331A KR1020237000380A KR20237000380A KR20230024331A KR 20230024331 A KR20230024331 A KR 20230024331A KR 1020237000380 A KR1020237000380 A KR 1020237000380A KR 20237000380 A KR20237000380 A KR 20237000380A KR 20230024331 A KR20230024331 A KR 20230024331A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237000380A
Other languages
English (en)
Korean (ko)
Inventor
다렌 켈리
미셸 파파디미트리우
크리스 번스
에릭 다니엘스
Original Assignee
오쿠렉스 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901856A external-priority patent/AU2020901856A0/en
Application filed by 오쿠렉스 피티와이 리미티드 filed Critical 오쿠렉스 피티와이 리미티드
Publication of KR20230024331A publication Critical patent/KR20230024331A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020237000380A 2020-06-05 2021-06-03 눈 장애의 치료를 위한 화합물 및 방법 Withdrawn KR20230024331A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020901856A AU2020901856A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901856 2020-06-05
AU2020901858A AU2020901858A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901858 2020-06-05
PCT/US2021/035749 WO2021247900A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Publications (1)

Publication Number Publication Date
KR20230024331A true KR20230024331A (ko) 2023-02-20

Family

ID=78829970

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000380A Withdrawn KR20230024331A (ko) 2020-06-05 2021-06-03 눈 장애의 치료를 위한 화합물 및 방법

Country Status (11)

Country Link
US (1) US20230270703A1 (enExample)
EP (1) EP4161527A4 (enExample)
JP (1) JP2023529845A (enExample)
KR (1) KR20230024331A (enExample)
CN (1) CN116033901A (enExample)
AU (1) AU2021284380A1 (enExample)
BR (1) BR112022024728A2 (enExample)
CA (1) CA3185849A1 (enExample)
IL (1) IL298733A (enExample)
MX (1) MX2022015327A (enExample)
WO (2) WO2021247901A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197681A1 (en) * 2021-03-17 2022-09-22 Occurx Pty Ltd Compounds for the treatment of disorders and salts and polymorphs thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
WO1997029744A1 (en) * 1996-02-15 1997-08-21 Kissei Pharmaceutical Co., Ltd. Neovascularization inhibitor
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
EP1008347A4 (en) * 1997-04-18 2002-02-06 Kissei Pharmaceutical REMEDIES FOR PROPHYLAXIS OR TREATMENT OF DISEASES RESULTING IN EXCESSIVE PROLIFERATION OF PIGMENTAL RETINE EPITHELIAL CELLS
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
JP2011006406A (ja) * 2009-05-29 2011-01-13 Santen Pharmaceut Co Ltd トラニラストを含有する網膜疾患の予防または治療剤
WO2012068612A1 (en) * 2010-11-24 2012-05-31 Fibrotech Therapeutics Pty Ltd Methods of treating eye diseases associated with inflammation and vascular proliferation
US10780070B2 (en) * 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight

Also Published As

Publication number Publication date
IL298733A (en) 2023-02-01
BR112022024728A2 (pt) 2023-03-07
CN116033901A (zh) 2023-04-28
MX2022015327A (es) 2023-02-22
US20230270703A1 (en) 2023-08-31
WO2021247900A1 (en) 2021-12-09
WO2021247901A1 (en) 2021-12-09
EP4161527A4 (en) 2024-06-26
CA3185849A1 (en) 2021-12-09
EP4161527A1 (en) 2023-04-12
AU2021284380A1 (en) 2023-01-19
JP2023529845A (ja) 2023-07-12

Similar Documents

Publication Publication Date Title
EP0799052B1 (en) New antithrombotic formulation, process for its manufacturing, and use thereof
EA023652B1 (ru) Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me)
KR20100134032A (ko) 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
JP6437456B2 (ja) ｛［１−シアノ−５−（４−クロロフェノキシ）−４−ヒドロキシ−イソキノリン−３−カルボニル］−アミノ｝−酢酸の結晶形態
KR20210002573A (ko) 간 질환에 호중구 엘라스타제 저해제의 사용
KR20140019361A (ko) 유효량의 （3ａＲ）－1，3ａ，8－트리메틸－1，2，3，3ａ，8，8ａ－헥사히드로피롤로〔2，3－ｂ〕인돌－5－일 페닐카바메이트 및 이의 제조방법
US20170020905A1 (en) Compositions and methods for treating an aggregation disease or disorder
CN114599357A (zh) 关节炎的治疗
JP2013511473A5 (enExample)
US20230270703A1 (en) Compounds and methods for the treatment of eye disorders
WO2017184875A1 (en) Composition and method for treating metabolic disorders
JP6490597B2 (ja) 眼の疾患および障害を治療するための方法
CN105992758B (zh) 包括含硫部分的糖衍生物和制备它们的方法以及使用它们治疗mps iiic的方法
US20220362215A1 (en) Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound
CN113260612B (zh) 用于治疗或预防肌营养不良症的化合物及其在医药用途中的治疗、改善或预防用衍生物
AU778148B2 (en) 2-aminotetralin derivatives for the therapy of glaucoma
WO2017151725A1 (en) Formulations of an s-nitrosoglutathione reductase inhibitor
CN116723836A (zh) 用于治疗急性心房颤动的舒欣啶施用
KR20210046115A (ko) 니아신 유도체 및 이를 함유하는 약학 조성물
KR20210141203A (ko) 에르도스테인 유도체 및 이를 함유하는 약학 조성물
EP3135280B1 (en) Tranilast for the treatment of cutaneous amyloidosis
KR101869741B1 (ko) 마시티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
KR20230156931A (ko) 질병의 치료를 위한 화합물 및 이의 염 및 다형체
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
HK40049529A (en) Compounds for treatment or prevention of muscular dystrophy and derivatives for treatment, amelioration or prevention in medical use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202